Aurinia Q2 2026: LUPKYNIS Sales Surge 19% to $79.4M, Net Income Hits $37.4M
AUPH sits 52% above its 52-week low of $10.34.
Summary
Aurinia's Q2 2026 results show LUPKYNIS sales accelerating to $79.4M (+19% YoY), net income of $37.4M, and strong cash generation. The Kezar acquisition closed, and the balance sheet remains robust with $443M in cash and investments.
Key Events · Earnings and Guidance · AUPH
-
LUPKYNIS Sales Growth Accelerates
Net product sales of $79.4M in Q2 2026, up 19% from $66.6M in Q2 2025, driven by deeper lupus nephritis market penetration.
-
Net Income More Than Doubles
Net income of $37.4M ($0.28 diluted EPS) vs $21.5M ($0.16) in Q2 2025, reflecting revenue growth and operating expense discipline.
-
Cash Generation Strengthens
Operating cash flow of $85.1M in H1 2026, up 87% YoY. Cash and investments totaled $443.1M at quarter-end, up from $398.0M at year-end 2025.
-
Kezar Acquisition Closed
Completed acquisition of Kezar Life Sciences on May 11, 2026 for $55.5M total consideration, adding aritinercept pipeline and $23.1M in deferred tax benefits.
Analysis · AUPH · Life Sciences
Aurinia delivered a strong quarter with LUPKYNIS net product sales up 19% year-over-year to $79.4 million, driving total revenue to $83.2 million. Net income reached $37.4 million, a 74% increase from the prior year, as operating leverage improved. The company generated $85.1 million in operating cash flow in the first half, ending the quarter with $443.1 million in cash and investments. The acquisition of Kezar Life Sciences closed in May, adding a pipeline asset and deferred tax benefits. The results confirm the commercial momentum of LUPKYNIS and a strengthening financial position, though the normalized tax rate now reflects full cash tax payments going forward.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AUPH was trading at $15.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.34 to $19.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.